On September 28, 2023, Jason McCarthy, an analyst at Maxim Group, made a noteworthy decision regarding Brainstorm Cell (NASDAQ:BCLI). McCarthy ...
BrainStorm Cell Therapeutics is experiencing a decline in its shares following the FDA Advisory Committee's decision on September 27, 2023. ...
On September 28, 2023, the FDA's Cellular, Tissue, and Gene Therapies Advisory Committee reached a majority decision of 17 to ...
On September 28, 2023, at 7:05:00 AM ET, the trading halt quotation resumption time was updated, indicating a potential interruption ...
Breaking News: Exciting Developments Unfold for BrainStorm Cell Therapeutics on September 28, 2023! In a highly anticipated turn of events, ...
On September 28, 2023, BrainStorm Cell Therapeutics Common Shares are set to resume trading at 7:10 a.m. ET, following a ...
Brainstorm Cell Therapeutics Inc (NASDAQ:BCLI) is currently experiencing a significant decline in its stock value as a result of the ...
Brainstorm Cell Therapeutics has experienced a decline in their stock price after the recent announcement from the FDA. The FDA ...
In preparation for the highly anticipated Cellular, Tissue, and Gene Therapies Advisory Committee meeting scheduled for September 27, 2023, a ...
Roth MKM, a renowned financial firm, has recently unveiled a groundbreaking report with a projected price target of $15 for ...